Atlas Trials

Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Clinical trial NCT06733987 · RECRUITING

Trial details

NCT number
NCT06733987
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Status
RECRUITING
Study type
OBSERVATIONAL
Hodgkin Lymphoma
Start date
2024-08-01
Primary completion
2027-02-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.